Locations:
Search
Phase 1 trial outcomes offer encouraging news for developing targeted therapy for solid tumors
Cleveland Clinic to administer first-of-its-kind T-cell therapy
Heavily pretreated patients experience improved progression-free survival and quality of life with CD20xCD3 therapy
Best practices for supporting patients with honesty and compassion
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Goal-of-care discussions drive earlier hospice access
Combination therapy improves outcomes, but lobular patients still do worse overall than ductal counterparts
Early results show strong clinical benefit rates
Standard of care is linked to better outcomes, but disease recurrence and other risk factors often drive alternative approaches
Multidisciplinary teams bring pathological and clinical expertise
Genetic variants exist irrespective of family history or other contributing factors
Advertisement
Advertisement